Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting
Maria-Isabel Jimenez-Serrania, Sara-Maria Martinez-Gonzalez, Javier Herradon-Muñoz, Carlos Treceño-Lobato · 2026
Read Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting by Maria-Isabel Jimenez-Serrania, Sara-Maria Martinez-Gonzalez, Javier Herradon-Muñoz, Carlos Treceño-Lobato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0352399.txt.
Description
Maria Jimenez-Serrania and three colleagues go hunting for drug side effects in pharmacy records before official systems notice them. Their 2026 pharmacovigilance study covers two modern diabetes drug families, the gliptins and the gliflozins. Community pharmacists surveyed treated patients with six months of recall. Metformin users served as the control group. Candidate drug-event pairs from the 2021 pharmacy data were then compared with Spain's spontaneous reporting database for later years.
Several early signals surfaced. One gliptin was linked with dry mouth. Another paired with bone fracture and with renal impairment. A gliflozin was tied to unusual fatigue. The statistical method, adapted from a validated Bayesian network, screened each pair for disproportion. Spontaneous reporting is slow and patchy by design. Pharmacists, who hear complaints first, could give regulators a head start. The authors frame these as candidate signals for confirmation, not established harms.
Catalog record
| CREATOR | Maria-Isabel Jimenez-Serrania, Sara-Maria Martinez-Gonzalez, Javier Herradon-Muñoz, Carlos Treceño-Lobato |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43345 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |